Oxurion N.V.
BRU: OXUR.BR0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Euronext Brussels
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Pascal Ghoson
- Employees
- 11
- Headquarters
- Leuven, Belgium
- IPO year
- 2006
- Market cap
- €266.4K
- Website
- https://www.oxurion.com
Loading OXUR…
Loading profile data…Frequently asked questions about OXUR
What does Oxurion N.V. (OXUR.BR) do?
Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for...
Where does OXUR.BR trade?
Oxurion N.V. (OXUR.BR) trades on the Euronext Brussels.
What sector is OXUR.BR in?
Oxurion N.V. (OXUR.BR) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Oxurion N.V.?
Pascal Ghoson is the chief executive officer of Oxurion N.V. (OXUR.BR).
Where is Oxurion N.V. headquartered?
Oxurion N.V. is headquartered in Belgium.
Does OXUR.BR pay a dividend?
Oxurion N.V. (OXUR.BR) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did OXUR.BR go public?
Oxurion N.V. (OXUR.BR) completed its initial public offering in 2006.